PCIA with morphine

PreclinicalSmall molecule

PCIA with morphine is one of 2 small molecule programs targeting Serratus Anterior Plane Block. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Serratus Anterior Plane BlockRecruiting

Serratus Anterior Plane BlockPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Serratus Anterior Plane Block

#DrugCompanyPhaseTrials

Bupivacain

IIstanbul University

Preclinical

2 2

PCIA with morphine

JJessa Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Serratus Anterior Plane Block

NCT06205875

Clinical

Trials by Indication[1]

Serratus Anterior Plane Block2 trials

High Versus Low Dose Serratus Anterior Plane Block After Minimally Invasive Valve Surgery.

Recruiting·JJessa Hospital·N/A·NCT06205875·100 enrolled

Serratus Anterior Plane Block Versus Standard of Care After Totally Endoscopic Aortic Valve Replacement

Completed·JJessa Hospital·N/A·NCT04699422·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PCIA with morphine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PCIA with morphine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PCIA with morphine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jessa Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJessa Hospital

PCIA with morphine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Serratus Anterior Plane Block2 trials

References

Drug Info

Quick Facts

Related News